DIAGNOSTICS
Apollo Hospitals to acquire Rs 103.2 crore stake in subsidiary Apollo Health
"... we wish to inform you that the Company is acquiring 35,12,107 equity shares of Rs 10 each at a price of Rs.294/- per share (including premium of Rs.284/- per share) aggregating to Rs. 1032.60 million by way of subscribing to the rights issue of Apollo Health and Lifestyle Limited, a subsidiary of the Company (AHLL)," the hospital chain company informed stock exchanges on Saturday.
Here's why waist-to-height ratio matters more than BMI in obesity diagnosis
Researchers have introduced a new diagnostic approach for obesity, focusing on waist-to-height ratio alongside BMI to better assess health risks linked to abdominal fat. Published in Nature Medicine and led by the European Association for the Study of Obesity (EASO), the framework highlights a waist-to-height ratio exceeding 0.5 as indicative of heightened cardiometabolic risks. By broadening criteria beyond BMI, the framework aims to improve early detection and treatment strategies, potentially revolutionizing how obesity-related health risks are managed in clinical settings.
Pressure on diagnostics industry will continue for another five years : A Velumani, Thyrocare Tech
Yes, there were challenges in diagnostic industry of a different nature in early 2000. There were no automations available adequately. Before year 2000 there were only two-three automations in the country and by another 10 years it became 500, another 10 years it has become literally 5,000.
Inclusive healthcare: H.E. Dr. Noura Khamis Al Ghaithi on Abu Dhabi’s vision beyond borders
In conversation with H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, who outlines the vision of the Abu Dhabi Global Healthcare Week (ADGHW) positioned to serve as an annual platform for inclusive knowledge-sharing and crafting collaborative strategies aimed at delivering positive patient outcomes.
Getting ready to end the 3-year exile: 5 stocks from diagnostics sector with upside potential of up to 53%
There are some businesses, where only a black swan event leads to sharp growth in profit. Otherwise the underlying nature is such that they don't have any sudden spike in their profits. But there is constant growth. The constant growth could be because of many reasons. It may be because of the fact that penetration of that good or service is very low and over a period of time as it improves, both top and bottom line keep moving upward. It could be because of the movement of business from the unorganized sector to the organized sector. Or due the fact that the “need” of that good or service is such that spending on it cannot be postponed. In the case of diagnostic business, it is all the three, or rather four. The fact is that in 2020, a black swan took place which led to the sudden spike in FY 2021 numbers, but then back to normal growth curve. Now for three years, there has been a painful process of partial normalization of valuation and end of price wars. Has the time come for extreme long term investors to bring them back on watchlist ?
KKR set to acquire Kerala's Baby Memorial Hospitals, make a comeback in hospital segment
KKR & Co plans to acquire a 70% stake in Kerala's Baby Memorial Hospital (BMH) for $300 million, marking its return to the Indian hospital sector. BMH, with 500 beds and expansion plans, is among Kerala’s largest hospitals. This move aligns with KKR’s strategy of expanding healthcare assets in India.
- Go To Page 1
India's healthcare in critical condition: 4 out of 5 public health centers below par, reveals new Govt report
A recent Indian government self-assessment reveals that most public health facilities, including district hospitals and primary centers, fall short of essential standards. Only 20% meet benchmarks for infrastructure and resources, with 42% scoring below 50%. Initiatives aim to bring 70,000 facilities to standard within 100 days, backed by inspections and funding under the National Health Mission. This highlights urgent reforms needed to enhance healthcare nationwide, promising better services and equity in healthcare delivery.
ET Analysis: Indian hospital chains report revenue growth & expansion plans amidst regulatory concerns
Leading hospital chains in India have reported improved average revenue per operating bed (ARPOB) and profitability in the latest quarter, driven by better payer mix and cost control measures. Expansion plans are underway, with a focus on markets like Bengaluru and Mumbai, through asset-light models. Adjacent businesses such as diagnostics, virtual care, and digital healthcare platforms are also seeing growth. However, regulatory proposals to rationalize rates may pose risks to sector valuations.
Apollo Hospitals Q4 Results: Net profit rises 76% YoY to Rs 254 crore
Revenue grew 15% YoY to Rs.4,944 crore in Q4FY24. The earnings before interest, tax, depreciation and ammortisation (EBITDA), EBITDA rose 31% YoY to Rs.640 crore in Q4FY24. The EBITDA margins expanded 161 basis points YoY to 12.95%.
SC refuses urgent hearing of Arvind Kejriwal's bail extension plea
The top court had on May 17 reserved its verdict on Kejriwal's plea against his arrest by the Enforcement Directorate (ED). Kejriwal was granted interim bail by the apex court on May 10 till June 1 to campaign for the Lok Sabha elections and was asked to surrender on June.
Another pandemic to happen soon? Here is what former UK chief scientific adviser said
Former UK government chief scientific adviser Sir Patrick Vallance warns that another pandemic is inevitable, urging the British government to focus on better surveillance and preparations as he believes we are not ready yet.
These two equity mutual fund categories offered negative returns in 3 month
Equity mutual fund categories - technology and pharma have lost up to 4% in the last three months, shows data. While technology-based funds have lost around 4.11%, the pharma and healthcare funds are down about 0.09% in the same period.
Healthcare firm Enhanced Innovations launches portable solar cooling device for rural areas
Enhanced Innovations' Phloton is an energy-agnostic device designed to improve efficiency of the delivery of medical supplies to the last mile.
Expect 15-18% upside in Sun Pharma over medium to long term: Hemang Jani
Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.
Metropolis Healthcare Q4 Results: Net profit rises 8% to Rs 36 crore
The diagnostic chain reported Rs 33.5 crore net profit in the corresponding quarter of the previous year. Revenue from operations grew by 11% YoY to Rs 313 crore.
Scientists call for more screening, awareness on inherited defects in anaemic patients in India
A study by scientists in India has highlighted inherited defects in anaemic patients in India. For the study, the researchers shortlisted nearly 300 anaemia cases from 2019 to 2022 after an initial screening. After excluding patients diagnosed with conditions such as inflammation and chronic bleeding, the team included 41 cases of suspected iron metabolism defects in their analysis.
The rising role of software in electric vehicles
Altigreen enhances 3Ws with software for battery management, motor control, diagnostics, telematics, user interface, and energy-saving algorithms. Data monetization and government support may offset costs.
Cipla ups investment in point-of-care testing firm Achira Labs
Cipla has announced further investment of up to Rs 26 crore in Achira Labs, a company specializing in point-of-care medical test kits. This investment will be made in four tranches, contingent upon the achievement of specific milestones. After the first tranche, Cipla will hold 27.27% of the total voting rights in Achira. This decision follows Cipla's initial acquisition of a 21.05% stake in Achira Labs in June 2022. Achira Labs, based in Bengaluru, focuses on developing and commercializing regulatory-approved medical diagnostic products using microfluidic technology.
Will try to grow better than last year without taking any price hikes: Shankha Banerjee, Dr Lal Pathlabs
We have been consistently saying that our EBITDA margin level would be around what we even see in our delivery in quarter four in the range of 26-27% kind of EBITDA margins, I think that is something which we continue to state is something which we are working towards.
Maharashtra: Government hospitals gear up to outsource critical services
Government hospitals in Maharashtra collaborate with private firms to introduce advanced diagnostic services. District hospitals play a crucial role in providing free treatments for various ailments. Meanwhile cardiac cath labs, and 10-year agreements aim to improve healthcare accessibility. Private players to operate MRI and CT scan facilities, billing at CGHS rates.
Do Dr Lal Pathlabs' results indicate a turnaround for the sector? 4 stocks from diagnostic space, 3 with upside potential of up to 31%
Some sectors have a company which can be called as the bell weather of that sector and that is why its results of that company probably are indicative of what is happening in the sector. In case of the diagnostic, it is probably the Dr Lals path labs which would fit the criteria, it has national presence, large network, present in both physical and digital segment. So when the quarterly numbers come and they show improvement on many fronts then probably it is time to have a look at them more seriously and see if there is a possible turnaround building in the sector. This became even more important because these stocks had gained extremely high valuation and also popularity in terms of both retail and institutional participation. But then for close to two years, they have been a strong under performer in a strong bull market. Does this result mean that finally in terms of price war for customer acquisition over and now the valuation readjustment will start in the upward direction.
Stock picks of the week: 4 stocks with consistent score improvement and upside potential of up to 39%
Last week’s movement of the market has brought back some memories of what happened in March 2024. Given the event risk in terms of election results, we might see higher volatility as some profit booking takes place. If one is not a trader and knows how to hedge, it would be better to be cautious before investing. If one is taking fresh exposure to equity, ensure that there is some level of quality as far as the business and fundamentals are concerned. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
Better suited for volatile market: 5 largecaps from different sectors with upside potential of up to 47%
In the last few days bears are not making any distinction between large or mid or small cap stocks they just crush everything, it might appear that there is no point in making a distinction between these segments of the market. But the fact is that periods like this are a reminder of many basic things which one should remember before taking any investment decision in equity. First and foremost, after buying a stock you will own a business and what business you own is more important than what is happening to nifty or any other indices. Second, if you are a real long term investor then short term corrections should not bother you as they have come in the past and they will come in future also. What one should look for is whether the underlying business is witnessing any change or not and whether that change is positive or negative for the business. Last but not the least, do your homework before investing and not after investing.
Diagnostics chains at inflexion point: Emkay
"With competitive intensity reducing after the emergence of the new normal post-pandemic, we believe Indian organised diagnostics chains stand at the cusp of inflexion," said the firm's analysts Anshul Agrawal and Eshan Bhargava in a client note."
Volatility is an integral part of market: 4 midcap stocks from different sectors with potential upside of up to 39%
As the market gets volatile, questions are bound to be raised about whether the mid-cap segment would see a sharp correction or not. Fears about the kind of correction which was seen in March are bound to resurface. More than anything, the best way to navigate such market conditions would be to do two things, first stay with mid-cap stock with some track record in terms of fundamentals and give return to shareholders. Second, once you pick the stock, stay with it long term and dont sell in hurry due to any narrative which some global and domestic development might bring on the table. The reason, volatility is part of any market, but that should not determine your long term investment decisions. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
Tackling volatility, qualitative & quantitative way: 4 small cap stocks with long term perspective
The way the market slipped on Friday, probably is another reminder that even the best of the bull market corrections are going to come. The problem with the corrective move is that if it sustains for longer, it is the small caps stocks which come under more pressure and shed an inordinate amount of weight. There is a technical reason for this, the liquidity in small caps stocks is lower as compared to large and midcaps. So, whenever there is a selling in this segment, the impact cost is always higher. But the other fact is that if one is able to hold on small at the time when correction is taking place, probability of more than normal return is also higher. But the question is how does one develop the ability to hold onto stocks when the narrative which is being governed by price action becomes so negative. The solution lies in combining a couple of things, which include qualitative and quantitative measure and last but not least ability to ignore noise.
Painful readjustment of valuations over? 4 stocks from diagnostics sector with upside potential of up to 31%
In the last four years, many sectors have made a comeback. However, there are few, who have probably a full life cycle in this short period of time. From all the love on the street which made them touch dizzy heights of valuations. Then a realization that the street is paying too much for them. It is about the diagnostic sector. From being part of a star portfolio manager tops picks, to him admitting that he made a mistake. Diagnostic stocks have seen a cycle. There is another side to the story. Every sector which goes through such cycles in the short term, tends to see a recovery. The only difference is the recovery time, both of the business and getting recognised once again by the street. So, these stocks will make a comeback, whether it happens in one quarter or after years is the question. But one thing is for sure, that if you are a long term investor, don't be in a hurry to get out of the sector.
ICMR invites suggestions from stakeholders for addition, deletion in diagnostics list
The Indian Council of Medical Research (ICMR) has invited suggestions from stakeholders to revise the National Essential Diagnostics List (NEDL) by the end of February. The list outlines the minimum number of diagnostic tests that should be available at various levels of healthcare facilities.
ICMR seeks suggestions for revision of national essential diagnostics list to enhance access to affordable healthcare
The Indian Council of Medical Research (ICMR) has invited suggestions for the revision of the National Essential Diagnostics List (NEDL), aiming to provide access to affordable and high-quality diagnostics at all healthcare levels. The list includes the minimum number of tests that should be available at various healthcare facilities, from village level to district hospitals.
Load More
